Latest News and Press Releases

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

NEWPORT BEACH, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” or the “Company”) announced that the Journal of Alzheimer’s...

NEWPORT BEACH, Calif., May 07, 2020 (GLOBE NEWSWIRE) --  Ault Life Sciences, Inc. (“ALSI” or the “Company”), a Delaware corporation, announced that it is seeking to raise up to $100 million through...

NEWPORT BEACH, Cal., May 01, 2020 (GLOBE NEWSWIRE) -- Ault Life Sciences™, Inc. (“ALSI” or the “Company”), a Delaware corporation, invites everyone interested in Alzheimer’s disease to watch an...

Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”)...